ArticleAntioxidants (Basel, Switzerland)2026
A Sanguinarine Analogue Targeting ROS Signaling Exhibits Anti-Tumour Effects by Inducing Apoptosis and Ferroptosis in Osteosarcoma.
Article in Antioxidants (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Osteosarcoma is a common malignant bone tissue tumour that frequently occurs in the adolescent population, with recurrence and metastasis rates that remain high under current treatment strategies, necessitating the development of cost-effective and efficient anti-osteosarcoma drugs. Sanguinarine, a benzophenanthridine alkaloid derived from plants in the Papaveraceae family, possesses anti-tumour capabilities; however, its clinical application is limited due to poor water solubility and potential organ toxicity. Through screening 30 sanguinarine analogues, in this study we found that analogue 25 exhibited significant activity and could suppress cell proliferation and arrest the cell cycle at the G0/G1 phase in U2OS and MG63 cells, with IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.